NCT05238701CompletedPhase 1
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 29 Jan 2024
Brief summary (registry, in English)
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- First submitted
- 9 Jan 2022
- Start date
- 25 Feb 2022
- Primary completion date
- 4 Nov 2023
- Lead sponsor
- Luye Pharma Group Ltd.
- Diseases
- Huntington's disease
- NCT number
- NCT05238701
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 104
- From 25 Feb 2022 to the primary completion date, 4 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution;
- Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial;
- Subject has used any of over-the-counter products within 14 days or prescription medications within 28 days prior to dosing;
- Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration;
- Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration;
- Subject who has participated in other clinical trials within 3 months before administration;
Other illness
- Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results;
- Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;.
- Subject has a history of self-mutilation; or at risk of suicide;
- Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust);
- Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results;
- Subject has a history of substance abuse or a positive urine drug screen;
- Other conditions which would make participation in the study unsuitable.
Lab values
- Subject has abnormal vital signs, laboratory abnormalities, and ECGs;
Other
- Subject who has daily smoking of ≥ 5 cigarettes;
- Subject has used blood products or being blood donor or blood loss;
- Pregnant, lactating women, or positive pregnancy test;
- Subject who refusal to contraception, or plan to donate sperm or ovums;
Who the study is looking for
- Subject who voluntarily participate and sign the informed consent form;
- Healthy male/female volunteers aged 18 to 45 years;
- Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) 18.5 \~ 28.0 kg/m2, inclusive;
- Able to comply with the lifestyle restrictions.
Age in the registry: 18 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Mental Health Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.